Anti-IgE Receptor (FcɛR1α) Autoantibody ELISA Kit

$520.00

The Eagle Bioscience’s Anti-IgE Receptor (FcɛR1α) Autoantibody ELISA Kit is intended for the quantitative determination of human anti-human IgE Receptor (FcεR1α) autoantibody levels in human serum or plasma samples. The test may be useful for detecting patients with chronic spontaneous urticaria who have developed autoantibodies (mainly IgG) to the IgE receptor. For research use only and not to be used in diagnostics procedures.

Anti-IgE Receptor (FcɛR1α) Autoantibody ELISA Kit

Anti-IgE Receptor (FcɛR1α) Autoantibody ELISA Kit was developed and manufactured in the US

Size: 1×96 wells
Dynamic Range: 0 – 100 U/mL
Sensitivity: 0.374 U/mL
Incubation Time: 1 hour 50 minutes
Sample Type: Serum, Plasma
Species Sample: Human
Sample Size: 100 µL

For Research Use Only


Specimen Collection and Storage

  • Only 10μL of human serum or plasma is required for anti-human IgE receptor antibody measurement in duplicate.
  •  In the case of serum, whole blood should be collected and must be allowed to clot for a minimum of 30 minutes at room temperature before the serum is separated by centrifugation (850 – 1500 x g for 10 minutes). The serum should be separated from the clot within three hours of blood collection and transferred to a clean test tube.
  • Serum or plasma samples should be stored at 2 – 8°C if the assay is to be performed within 72 hours.
  • Avoid repeated (more than three times) freezing and thawing of the specimen.

Assay Principle

This ELISA is designed, developed and produced for the quantitative measurement of human anti-hIgE receptor (FcεR1α) autoantibodies in serum and plasma samples.

Assay calibrators, controls and diluted patient samples are directly added to wells of a microplate that is coated with recombinant human IgE receptor protein. After the first incubation period, anti-IgE receptor antibodies bind to the human IgE receptor protein on the wall of microtiter well and unbound proteins in each microtiter well are washed away. Highly purified Protein A labeled with horseradish peroxidase is then added to each microtiter well. After the second incubation period, a complex of coated human IgE receptor ̶ Anti- hIgE receptor antibody ̶ peroxidase-labeled Protein A is formed. The unbound protein is removed in the subsequent washing step. The wells are then incubated with a substrate solution in a timed reaction and subsequently measured in a spectrophotometric microplate reader. The enzymatic activity of the immunocomplex bound to the IgE receptor protein on the wall of the microtiter well is directly proportional to the amount of anti-IgE receptor antibody in the sample. A calibration curve is generated by plotting the absorbance versus the respective anti-IgE receptor concentration for each calibrator on a cubic spline curve fit. The concentration of IgE receptor antibody in test samples is determined directly from this calibration curve.


Related Products

Coronavirus COVID-19 IgG ELISA Assay Kit
Anti-IgE Antibody ELISA Kit
Canine IgE ELISA Assay

Documents

Product Manual


Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.

Additional Information

Assay Background


The presence of anti-IgE receptor (FcεR1α) antibodies in patient serum or plasma has been associated with chronic spontaneous urticaria (CSU), which is a common skin disorder affecting 0.5% to 1.8% of the general population. It is characterized by repeated occurrence of short-lived cutaneous wheals accompanied by redness and itching. Although the CSU symptoms are very much similar to those of acute urticaria triggered by allergens, in most CSU cases, there is no definite identifiable and direct external triggering factor.

The pathogenesis of CSU has not yet been fully elucidated, but a proportion of patients with CSU have been found to have functional autoantibodies. In CSU patients, circulation human anti-FcεR1α autoantibodies are seen in 30% to 60% and anti-IgE autoantibodies in 5% to 10%. These human autoantibodies are mainly IgG subtype.

Product Citations